Vectans pharma is proud to announce that its one-per-episode Lauriad^® aciclovir treatment tablet for herpes labialis, Sitavig^® 50mg, has received the approbation of the ANSM for OTC commercialization in France. Issued from Lauriad technology, SITAVIG ensures an optimum and efficient localized concentration of acyclovir directly at the disease site.
A big step for Vectans , but also for the many patients in France prone to recurrent